Aradigm Corporation (NASDAQ:ARDM) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, May 23rd.

According to Zacks, “Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung. “

Aradigm Corporation (ARDM) traded down 1.95% during trading on Tuesday, reaching $1.51. The company’s stock had a trading volume of 1,317 shares. The stock has a 50-day moving average of $1.27 and a 200 day moving average of $1.64. Aradigm Corporation has a one year low of $0.78 and a one year high of $7.19. The firm’s market capitalization is $22.64 million.

Aradigm Corporation (NASDAQ:ARDM) last released its quarterly earnings data on Monday, May 15th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.18. Aradigm Corporation had a negative return on equity of 665.03% and a negative net margin of 1,515.94%. The firm had revenue of $1.69 million for the quarter. On average, equities research analysts predict that Aradigm Corporation will post ($1.10) EPS for the current fiscal year.

WARNING: “Aradigm Corporation (ARDM) Lowered to “Sell” at Zacks Investment Research” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/06/22/aradigm-co-ardm-downgraded-by-zacks-investment-research-updated-updated-updated.html.

A hedge fund recently bought a new stake in Aradigm Corporation stock. Paulson & CO. Inc. acquired a new position in shares of Aradigm Corporation (NASDAQ:ARDM) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 192,727 shares of the company’s stock, valued at approximately $308,000. Paulson & CO. Inc. owned about 1.30% of Aradigm Corporation at the end of the most recent quarter. 38.02% of the stock is owned by institutional investors and hedge funds.

Aradigm Corporation Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Get a free copy of the Zacks research report on Aradigm Corporation (ARDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related stocks with our FREE daily email newsletter.